DNA — Ginkgo Bioworks Holdings, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1830214 ·
Last close
$6.78
Market Cap
$375.50M
52W High
$11.14
52W Low
$6.47
ADV30
1,074,776
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 20,156,000 | 18,437,000 | -58,548,000 | -46,710,000 | 990,046,000 | 84,535,000 | 569,762,000 |
| Mar 2026 | 19,474,000 | 16,376,000 | -71,374,000 | -82,587,000 | 1,033,075,000 | 143,864,000 | 589,922,000 |
| Dec 2025 | 33,396,000 | 26,095,000 | -70,046,000 | -80,751,000 | 1,119,696,000 | 167,202,000 | 611,106,000 |
| Sep 2025 | 38,837,000 | 26,035,000 | -88,272,000 | -80,755,000 | 1,189,165,000 | 111,065,000 | 629,382,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-178,360,000
Investing CF
$56,502,000
Financing CF
$34,550,000
CapEx
$-4,595,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.69
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-6,279,617,000
Inventory
—
Receivables
$13,013,000
ST Investments
$217,628,000
EBIT TTM
$-297,960,000
Pretax Income TTM
$-295,480,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$132,421,000
EBITDA
$-261,624,992
Free Cash Flow
$-72,398,248
Enterprise Value
$558,517,056
Total Cash
$302,163,008
Total Debt
$404,112,992
Shares Out
55,383,808
Trailing EPS
$-4.88
Book Value
$6.60
ROE
-59.9%
ROA
-16.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,155,000 | -303,880,000 | -312,763,000 | 1,119,696,000 | 611,106,000 | — | -171,059,000 |
| Dec 2024 | 227,043,000 | -487,727,000 | -547,029,000 | 1,377,449,000 | 661,391,000 | — | -319,585,000 |
| Dec 2023 | 251,455,000 | -768,196,000 | -892,869,000 | 1,665,342,000 | 568,190,000 | — | -295,500,000 |
| Dec 2022 | 477,706,000 | -2,208,952,000 | -2,104,929,000 | 2,539,321,000 | 803,044,000 | — | -252,198,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.90
Max Pain — expiry 2026-09-18
max pain strike: $7.00 · spot: $6.95 · call oi: 5,607 · put oi: 1,849
Expected Move to 2026-09-18:
±$1.29
(18.56%) —
implied range
$5.66 –
$8.24
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | $383.88M | $2.12 | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $399.77M | $11.40 | — |
| XFOR | X4 Pharmaceuticals, Inc | $401.54M | $4.05 | — |
| PALI | PALISADE BIO, INC. | $350.28M | $2.01 | — |
| LXEO | Lexeo Therapeutics, Inc. | $403.67M | $4.92 | — |
News headlines (Yahoo Finance, 1h cache)
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts
2026-05-13 11:41 · Yahoo
Ginkgo Bioworks Q2 Earnings Call Highlights
2026-08-08 04:03 · Yahoo
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
2026-05-26 16:33 · Yahoo
Ginkgo Bioworks Q1 Earnings Call Highlights
2026-05-10 03:05 · Yahoo
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
2026-05-07 20:05 · Yahoo
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
2026-04-30 12:01 · Yahoo
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
2026-08-11 18:00 · Yahoo
Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab?
2026-05-22 12:36 · Yahoo
How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut
2026-05-11 19:13 · Yahoo
Ginkgo Bioworks Holdings, Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.